Fluoxetine or Venlafaxine for Early Post Stroke Depression

• Published in: Neurology India Vol. 70; no. 6; pp. 2407 - 2410
• Main Authors: Nambiar, Vivek, Parvathy, J, Philip, Tania, Abhijith, K, Sreeni, S, Panicker, Naveen, Ajai, Amrutha, Dhanya, T
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer India Pvt. Ltd 01-11-2022; Medknow Publications and Media Pvt. Ltd; Medknow Publications & Media Pvt. Ltd
• Subjects: Care and treatment; Complications and side effects; Cyclohexanols - adverse effects; Depression; Depression, Mental; Female; Fluoxetine; Fluoxetine - adverse effects; Humans; Male; Patient outcomes; Psychological aspects; Stroke; Stroke (Disease); Venlafaxine; Venlafaxine Hydrochloride; India; venlafaxineKey Message: Depression following stroke can hamper the progress of the patient both physically as well as socially and hence should be given proper attention and management. The evidences for prevention and management of PSD are still limited. From our study; Venlafaxine has got better efficacy and safety profile compared to fluoxetine in this group of patients; fluoxetine; post stroke depression; Antidepressants; venlafaxine
• ISSN: 0028-3886; 1998-4022
• DOI: 10.4103/0028-3886.364069

Context: Post stroke depression (PSD) is an under diagnosed morbidity of stroke and can negatively affect the prognosis of the patient.
Aims: We intended to study the prevalence of PSD and the commonly used anti-depressants and their outcome in patients with PSD.
Settings and Design: A prospective observational study was conducted in the patients admitted to the stroke unit of a tertiary care centre.
Methods and Materials: Diagnosis of post stroke depression was made by the Hamilton Depression Rating Scale (HDRS) during the two-week period after stroke or in the clinic follow up. A comparison of clinical outcome and adverse events of the two anti-depressants used, i.e. venlafaxine and fluoxetine were done by a follow up of up to 6 months.
Statistical Analysis Used: Independent sample test was used for statistical purposes in the study
Results: Out of the 326 stroke patients admitted in the department, 73 had PSD and 60 patients out of this were assigned into the study. Forty patients were males, and the mean age of the sample population was found to be 62.13 ± 11.14. Major risk factors identified were hypertension, diabetes mellitus, and dyslipidemia. Venlafaxine showed better outcome and less adverse events compared to fluoxetine. Major adverse events observed were hyponatremia, headache, insomnia, and anxiety.
Conclusions: PSD in the early phase affects a substantial number of the stroke patients. Venlafaxine has got a better outcome and adverse event profile compared to fluoxetine in this group of patients. However, larger multicenter studies will provide more helpful data in this area.